

Docket No. PRD2170USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Freyne, Eddy J. et al.

Serial No. : 10/596,512

Art Unit: 1624

Filed

: December 15, 2004

Examiner:

For

: PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES

AS ANTI-PROFILERATIVE AGENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30, 2006 (Date of Deposit)

Alana G. Kriegsman
(Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/

(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.

☐ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with ☐ the
first or ☐ second After Final Submission, therefore:

∐ In a	ccordance with §1.129(a), this Information
Disclosure Stat	tement is being filed in connection with [] the
first or 🗌 seco	and After Final Submission, therefore:
	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of \$180.00 as set forth
	in §1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of \$180.00 as set forth
	in §1.17(p).
	aggordange with \$1.07/d) this Information
	accordance with §1.97(d), this Information
	atement is being filed after the mailing date of
	Action under §1.113 or a Notice of Allowance
	but before the payment of the Issue Fee.
	nereby petition(s) for consideration of this
	sclosure Statement. Included are: Statement in
	th §1.97(e) as set forth below and the fee of
\$180.00 as set	forth in §1.17(p).
	ies of each of the references listed on the
attached Form	PTO-1449 are enclosed herewith.
	ies of references listed on the attached Form PTO-
1449 are enclo	osed herewith EXCEPT THAT:
	To originate of the conforming of the conformation of the conforma
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
П	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	chacavor to bappry copies at the mainther s
	request.
⊠ Copi	request.

. .

 \boxtimes There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: \boxtimes Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2170USPCT/AGK. This form is submitted in triplicate. Respectfully submitted, /Alana G. Kriegsman/ Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants Johnson & Johnson

. -------

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: October 30, 2006

.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

collection of information unless it displays a valid OMB control number.					
10/596,512					
12/15/2004					
Eddy J. Freyne					
1624					
PRD2170USPCT					

Date of Publication | Pages, Columns, Lines,

				U.S. PATENT DOCUMENTS			
		U.S. Patent Do	cument		Date of Publication	Pages, Columns, Lines,	
Examiner	Cite		Kind Code ²	Name of Patentee or Applicant	of Cited Document	where relevant passages or	
Initials No.1 Nu		Number	(if known)	of Cited Document	mm-dd-yyyy	where relevant passages of relevant figures appear	
						11	

				.			
,							

FOREIGN PATENT DOCUMENTS Foreign Patent Document

			Name of Patentee or	of Cited Document	where relevant								
Examiner Initials								Office ³	Number⁴ K	KindCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear
		wo	95/19774	A1	Warner-Lambert Company	07-27-1995							
		wo	96/07657	A1	Dr. Karl Thomae GMBH	03-14-1996							
		wo	97/32880	A1	Dr. Karl Thomae GMBH	09-12-1997							

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control conditions. Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a valid OMB control number.					
Application Number	10/596,512				
Filing Date	12/15/2004				
First Named Inventor	Eddy J. Freyne				
Group Art Unit	1624				
Examiner Name					
Attorney Docket Number	PRD2170USPCT				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	2
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.1	publisher, city and/or country where published	
		BROWN et al., "High Throughput Screening", 1997, editors: Devlin, John P., Publishers: Dekker, New York, N.Y., pages	
		317-328.	
		BURKE, Terrence R. Jr., "Protein-tyrosine Kinase Inhibitors", <u>Drugs of The Future</u> , 1992 , pages 119-131, Vol. 17, No. 2.	
		DAVIES et al., "Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors", <u>Biochemical</u> Society, 2000 , pages 95-105, Vol. 351.	
		DELIA, Thomas, "Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotriazines.", Heterocyclic Compounds, John Wiley & Sons, Inc., Interscience Publications, pages 261-304.	
		DRUKER et al., "Lessons Learned From The Development of An Abl Tyrosine Kinase Inhibitor For Chronic Myelogenous Leukemia". The Journal of Clinical Investigation, January 2000, pages 3-7, Vol. 5, No. 1.	
		ELDER et al., "Overexpression of transforming growth factor alpha in psoriatic epidermis", <u>Science</u> , 1989 , pages 811-814, Vol. 243.	
		GENNARO et al. Remington's Pharmaceutical Sciences, 19 th ed., Mack Publishing Company, 1990 , see especially Part 8: Pharmaceutical preparations and their Manufacture,.	
		MORIN, Michael J., "From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-tumor and Anti-angiogenic Agents", Oncogene, 2000, pages 6574-6583, Vol. 19.	
		NAGAMATSU et al., "Sytheses of 3-Substituted 1-Methyl-6-Phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones (6-Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.", Chem Pharm Bull., 1993, pages 362-368, Vol 41, No. 2.	
		NAGAMATSU et al., "General Syntheses of 1-Alkyltoxoflavin and 8-Alkylfervenulin Derivatives of Biological Significance By The Regioselective Alylation of Reumycin Derivatives And The Rates of Transalkylation From 1-Alkyltoxoflavins Into Nucleophiles." J. Chem. Soc. Perkin Trans. 1, 2001. pages 130-137.	
		SHAWVER et al., "Smart Drugs: Tyrosine Kinase Inhibitors In Cancer Therapy", Cancer Cells, March 2002, pages 117-123, Vol 1.	
	L		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Application Number	10/596,512
Filing Date	12/15/2004
First Named Inventor	Eddy J. Freyne
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	PRD2170USPCT

Page 1 of 1

	U.S. PATENT DOCUMENTS							
	U.S. Patent Document							
	Name of Patentee or Applicant				10	10.12	Pages, Columr	
Examiner Initials	Cite	of Cited Document				d Code ²	where relevant passages or	
initials	No.1		Num	ber	(IT	known)	relevant figure	s appear
	\vdash							<u></u>
		497.10						
<u> </u>								

		. •						
	<u> </u>		<u> </u>					
		FOREIGN	N PATEN	DOCUMENT	S			
			Foreign I	Patent Document			Columns, Lines,	
l		Name of Patentee or	_				elevant passages	
Examiner Initials	Cite	Applicant of Cited Document	Office ³	Number⁴ Ki	indCode⁵	or re	levant figures appear	T ⁶
illitials	No. ¹		Office	Noniber 10	ind Code			
								···· ····
ļ					ļ	<u> </u>		
•								
				+		 		
								ł
					 -	-		
		OTHER PRIOR ART - NO	ON PATEN	IT LITERATURE	DOCUMEN	ITS		
		Include name of the author (in Ca	APITOL L	ETTERS), title	of the artic	cle (when		
Examiner	Cite	title of the item (book, magazine						T²
's Initials*	No. ¹	volume-issue number(s), publish	er, city and/or o	country wn	ere publis	snea	
muais		PCT Intl. Search Report, PCT/EP2004/0	053501 Ar	ril 28, 2005				
		_						
		<u> </u>						L
Examiner				Date				
Signature				Considered				